A rare breast tumor: solid neuroendocrine carcinoma

25.00

COD: 081-86 Categorie: ,

Alessandro Sanguinetti, Stefano Santoprete, Roberta Lucchini, Roberta Triola, Fabio Loreti, Nicola Avenia

Ann. Ital. Chir., 2013 84: 81-85
aheadofprint 31 May 2012

La mia nuova descrizione qui!

Price of a print issue €25.00

inflammatory primary solid neuroendocrine carcinoma of breast managed by surgery and chemotherapy and a brief review
of the epidemiology, clinical features, diagnosis, pathologic features, treatment, and prognosis of solid NECB.
METHODS: A 63-year-old woman was admitted in our institution with inflammatory primary solid neuroendocrine carcinoma
of breast. A bulky mass of 6,5 cm tumor was located in the upper-outer and intern quadrant of her right
breast. The patient underwent neo-adjuvant chemotherapy, and subsequent radical mastectomy with axillary lymph node
dissection. Microscopically, the tumor was classified as solid cohesive, the tumor cells were positive for neuroendocrine
markers chromogranin A and synaptophysin. 19 lymph nodes of 27 were metastatic.
RESULTS: Local recurrence and metastatic progression was noted only one month after the surgery, the patient was managed
by chemotherapy and hormone-therapy. She is still alive, 24 months after diagnosis.
CONCLUSIONS: Solid neuroendocrine carcinoma is a subtype of mammary carcinoma with several distinctive features.
Because of the rarity of this disease, there is no standard treatment, they are characterized by a higher propensity for
local and distant recurrence, This case reinforces the importance to explore the novels therapeutics regimen and one of
ways to explore is the use of VP16-cisplatine as treatment as it was partially efficacy for this kind of tumor.

0

Utilizzando il sito, accetti l'utilizzo dei cookie da parte nostra. maggiori informazioni

Questo sito utilizza i cookie per fornire la migliore esperienza di navigazione possibile. Continuando a utilizzare questo sito senza modificare le impostazioni dei cookie o cliccando su "Accetta" permetti il loro utilizzo.

Chiudi